1-9 of 9
Rohan Medhekar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Systematic Literature Review and Meta-Analysis of Comparative Clinical Evidence Investigating Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) As First-Line Treatment for Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Lucio Gordan, Rohan Medhekar, Alex Z. Fu, Abril Oliva Ramirez, Nicolle Bonar, Bao-Ngoc Nguyen, Michaela Spence, Rebecca McTavish, Tim Disher, Shuchita Kaila, Anjan J. Patel
Journal: Blood
Blood (2023) 142 (Supplement 1): 1963.
https://doi.org/10.1182/blood-2023-180829
Published: 2023
Journal Articles

A US National View of Prevalent and Newly Diagnosed Multiple Myeloma in 2021: A Retrospective Analysis of National All-Payer Claims Database

Dee Lin, Yihang Liu, Nina Kim, Savanna Ledford, Aerin Sun, Kimberly Brunisholz, Rohan Medhekar, Lisa Abramovitz, Keshia Maughn, Victor Johnson, Michael Schultz, Bingcao Wu
Journal: Blood
Blood (2022) 140 (Supplement 1): 932–933.
https://doi.org/10.1182/blood-2022-167474
Published: 2022
Journal Articles

Characteristics and Outcomes of Non-Transplanted Patients with Newly Diagnosed Multiple Myeloma (NDMM) Initiating Treatment with Bortezomib, Lenalidomide, and Dexamethasone (VRd) As First-Line of Therapy

Rohan Medhekar, Tao Ran, Alex Z. Fu, Sharmila Patel, Shuchita Kaila
Journal: Blood
Blood (2021) 138 (Supplement 1): 3782.
https://doi.org/10.1182/blood-2021-153416
Published: 2021
Journal Articles

Carfilzomib 56mg/m2 Twice-Weekly in Combination with Dexamethasone and Daratumumab (KdD) Versus Daratumumab in Combination with 8 Cycles of Bortezomib and Dexamethasone (DVd); A Matching-Adjusted Indirect Treatment Comparison

Katja Weisel, MD, Ajay Nooka, MDMPH, Evangelos Terpos, MDPhD, Andrew Spencer, Hartmut Goldschmidt, MD, Istvan Majer, PhD, Lucy DeCosta, MSc, Rohan Medhekar, PhD, Akeem Yusuf, PhD BPharm, Shaji K. Kumar, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–9.
https://doi.org/10.1182/blood-2020-141995
Published: 2020
Journal Articles

Evolving Unmet Need in Patients Refractory to Lenalidomide: Overview of the Clinical Trials in Relapsed/Refractory Multiple Myeloma

Maria-Victoria Mateos, MD PhD, Rohan Medhekar, PhD, Istvan Majer, PhD, Mehmet Turgut, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-142642
Published: 2020
Journal Articles

Could Patients with Multiple Myeloma (MM) Derive Additional Benefit from Their Treatments? Real-World Evidence for Carfilzomib Dosing Intensity on Survival and Treatment Progression

Rohan Medhekar, PhD, Dionne Hines, MPH, PhD, Sumeet Panjabi, PhD, Tim Welliver, MD PhD, Xin Wang, PhD, Rolin L. Wade, RPh, MS
Journal: Blood
Blood (2018) 132 (Supplement 1): 836.
https://doi.org/10.1182/blood-2018-99-113414
Published: 2018
Journal Articles

Economic Burden of Stem Cell Transplant Among Patients with Multiple Myeloma

Sikander Ailawadhi, Sumeet Panjabi, PhD, Nicole Princic, MS, Rob Fowler, MS, Oth Tran, MA, Francesca Gatta, MSc, BSc, Rohan Medhekar, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3427.
https://doi.org/10.1182/blood.V130.Suppl_1.3427.3427
Published: 2017
Journal Articles

Carfilzomib Dosing Patterns and Time to Next Treatment Among Adult Patients with Multiple Myeloma Treated in the US Community Oncology Setting

Robert M Rifkin, MD, E Susan Amirian, PhD MS, Rohan Medhekar, PhD, Thomas Wilson, PhD DrPH, Marley Boyd, MS, Khalid Mezzi, MD MBA, Sumeet Panjabi, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3433.
https://doi.org/10.1182/blood.V130.Suppl_1.3433.3433
Published: 2017
Journal Articles

A Real-World Comparative Analysis of Carfilzomib and Other Systemic Multiple Myeloma Chemotherapies in the US Community Oncology Setting

Robert M Rifkin, MD, Rohan Medhekar, PhD, E Susan Amirian, PhD MS, Thomas Wilson, PhD DrPH, Marley Boyd, MS, Khalid Mezzi, MD MBA, Sumeet Panjabi, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3434.
https://doi.org/10.1182/blood.V130.Suppl_1.3434.3434
Published: 2017